

Supplementary table 1.

Entry terms and Medical Subject Headings (MeSH) terms utilized in each database search.

Database	#1 Morphea	#2 Ustekinumab	Results
MEDLINE	morphea[Mesh] OR "morphea"[tiab] OR "localized scleroderma"[tiab] OR "localised scleroderma"[tiab] OR "circumscribed scleroderma"[tiab] OR "scleroderma, localized"[Mesh] OR "morpheaform"[tiab] OR "sclerodermoid"[tiab] OR fibrosing dermatosis"[tiab] OR "fibrosing skin disease"[tiab] OR "fibrosing disorder"[tiab]	ustekinumab[Mesh] OR ustekinumab[tiab] OR "Stelara"[tiab] OR "anti-IL-12/23"[tiab] OR "anti-IL-12/23"[tiab] OR "IL-12/23 inhibitor"[tiab] OR "interleukin 12/23 inhibitor"[tiab] OR "IL12/23 inhibitor"[tiab] OR "interleukin-12 and interleukin-23 inhibitor"[tiab]	7
Web of Science	TS=(morphea OR "localized scleroderma" OR "localised scleroderma" OR "circumscribed scleroderma" OR "scleroderma, localized" OR morpheaform OR sclerodermoid OR "fibrosing dermatosis" OR "fibrosing skin disease" OR "fibrosing disorder")	TS=(ustekinumab OR "Stelara" OR "anti-IL-12/23" OR "anti-IL-12/23" OR "IL-12/23 inhibitor" OR "interleukin 12/23 inhibitor" OR "IL12/23 inhibitor" OR "interleukin-12 and interleukin-23 inhibitor")	5
SciELO	(morphea OR "localized scleroderma" OR "localised scleroderma" OR "circumscribed scleroderma" OR "scleroderma, localized" OR morpheaform OR sclerodermoid OR "fibrosing dermatosis" OR "fibrosing skin disease" OR "fibrosing disorder")	(ustekinumab OR "Stelara" OR "anti-IL-12/23" OR "anti-IL-12/23" OR "IL-12/23 inhibitor" OR "interleukin 12/23 inhibitor" OR "IL12/23 inhibitor" OR "interleukin-12 and interleukin-23 inhibitor")	0

[medical subject heading (MeSH)]: MeSH descriptor; [tiab]: search limited to the title and abstract fields; TS: search for topic terms in the following fields within a record.

Supplementary table 2.

Quality assessment of the studies included in the systematic review.

Publication (year)	JBI Critical Appraisal Checklist for Case Reports								Quality rating
	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8	
Corral Magana (2017)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Good (8)
Steuer (2019)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Good (8)
Makihara-Inukai (2021)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Good (8)
Tabak (2022)	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Good (7)
Cirone (2023)	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Moderate (6)
Shaffer (2024)	Yes	No	No	Yes	Yes	Yes	Yes	Yes	Moderate (6)

Q1: Were patient's demographic characteristics clearly described?; Q2: Was the patient's history clearly described and presented as a timeline?; Q3: Was the current clinical condition of the patient on presentation clearly described?; Q4: Were diagnostic tests or assessment methods and the results clearly described?; Q5: Was the intervention(s) or treatment procedure(s) clearly described?; Q6: Was the post-intervention clinical condition clearly described?; Q7: Were adverse events (harms) or unanticipated events identified and described?; Q8: Does the case report provide takeaway lessons?; JBI: Joanna Briggs Institute; Risk of bias classification based on the proportion of "Yes" responses: low (7–8), moderate (5–6), high (≤ 4) out of 8 checklist.